Gain insight into the optimal use of checkpoint inhibitors for patients with advanced/metastatic lung cancer and learn the current and emerging use in the treatment of non-small cell lung cancer (NSCLC). Furthermore, explore the practical considerations on using PD-L1 testing in clinical care and how to manage immune-related adverse events. This activity features expert faculty video presentations with downloadable slides from our satellite symposium held in conjunction with the ESMO 2017 Congress in Madrid, Spain.
1.25 AMA PRA Category 1 Credits™
Oct 20, 2017
Oct 20, 2018
Current uses of checkpoint inhibitor therapy in the treatment of NSCLC
Enriqueta Felip, MD, PhD
Biomarkers in clinical practice: Benefits and limitations
Marina Garassino, MD
Incorporating checkpoint inhibitors into the management of NSCLC: An interactive exercise
David Planchard, MD, PhD, and Faculty Panel
Early identification and optimal management of immune-related adverse events (irAEs)
Jürgen R. Fischer, MD
Managing the irAEs seen with checkpoint inhibitor therapy: An interactive exercise
David Planchard, MD, PhD, and Faculty Panel
Safety and efficacy of emerging checkpoint inhibitors in NSCLC
Naiyer Rizvi, MD
Assessing what you have learned from this activity: Have you increased your knowledge base?
David Planchard, MD, PhD
David Planchard, MD, PhD
David Planchard, MD, PhDGustave Roussy
Enriqueta Felip, MD, PhDVall d’Hebron University Hospital
Jürgen R. Fischer, MDKlinik Löwenstein gGmbH
Marina Garassino, MDFondazione IRCCS - Istituto Nazionale dei Tumori
Naiyer Rizvi, MDNew York-Presbyterian Hospital
Columbia University Medical Center
New York, New York, United States
This educational activity is specifically designed to meet the needs of medical oncologists, pulmonologists, and other multidisciplinary specialists involved in the treatment of patients with NSCLC.
After successful completion of this educational activity, participants should be able to:
- Assess recent data on the efficacy/safety of checkpoint inhibitor therapy for the treatment of NSCLC
- Implement appropriate treatments for NSCLC that incorporate the use of checkpoint inhibitors
- Analyze recent efficacy and safety data on emerging checkpoint inhibitors, alone and in combination with other agents, in the treatment of NSCLC
- Describe the benefits and limitations of using PD-L1 as a biomarker to guide treatment selection when managing NSCLC
- Develop management strategies to address irAEs related to the use of checkpoint inhibitors
This educational activity is supported by a grant from AstraZeneca Pharmaceuticals LP.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
prIME Oncology designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring activity is provided by prIME Oncology.
Method of Participation
Links to the posttest are available on the video player pages.
In order to receive credit, participants must successfully complete the online posttest with 75% or higher.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Felip has disclosed that she received consulting fees from Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Pfizer, and Roche. She also received lecture fees for participating in speaker bureaus from AstraZeneca, Bristol-Myers Squibb, and Novartis. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr Fischer has disclosed that he received consulting fees from AstraZeneca, Bristol-Myers Squibb, Celgene, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Garassino has disclosed receipt of consulting fees, research support or performance of contracted research, and fees for non-CME services for her role on advisory boards from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Inivata Limited, Merck Sharp & Dohme, Merck Sharp & Dohme International GmbH, Novartis, Novartis Farma, Otsuka Pharma, and Roche. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr Planchard has disclosed that he received consulting fees from AstraZeneca, Bristol-Myers Squibb, Boehringer, Merck Sharp & Dohme, Novartis, Pfizer, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Rizvi has disclosed that he received consulting fees from AstraZeneca, Bristol-Myers Squibb, Lilly, Merck, Novartis, Pfizer, and Roche. He also has ownership interest in ARMO Biosciences and Gritstone Oncology. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:
- Ronald Viggiani, MD (medical director content reviewer/planner) – no relevant financial relationships
- Sanneke Koekkoek, RN (scientific content reviewer/planner) – no relevant financial relationships
- Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.